Zoetis Inc. $ZTS Shares Acquired by Ritholtz Wealth Management

Ritholtz Wealth Management raised its stake in Zoetis Inc. (NYSE:ZTS) by 7.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,725 shares of the company’s stock after acquiring an additional 1,663 shares during the period. Ritholtz Wealth Management’s holdings in Zoetis were worth $3,544,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares during the period. Finally, REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $142.08 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a market cap of $62.97 billion, a P/E ratio of 24.45, a PEG ratio of 2.30 and a beta of 0.90. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The company has a 50-day moving average price of $148.89 and a 200 day moving average price of $154.03.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ZTS. Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Zoetis has an average rating of “Hold” and an average target price of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.